Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Asthika Goonewardene maintains a 'Buy' rating on Autolus Therapeutics (NASDAQ:AUTL) and raises the price target from $6 to $9.
August 17, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a 'Buy' rating on Autolus Therapeutics and raises the price target from $6 to $9, which could lead to a positive market reaction.
The raised price target by Truist Securities indicates a positive outlook for Autolus Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100